Children’s Hospital of Philadelphia (CHOP) announced today that the National Academy of Medicine (NAM) named Lindsey A. George, MD, Director of Clinical In Vivo Gene Therapy, and an attending physician in the Division of Hematology at CHOP, as a member of its 2026 class of Emerging Leaders in Health and Medicine (ELHM) scholars. The ELHM program spotlights early- to mid-career professionals driving innovation across disciplines including artificial intelligence in medicine, cell and gene therapy, nanomedicine, maternal-fetal health, health economics and carceral health.
Dr. George is a physician-scientist focused on studying the molecular basis of blood clotting and developing gene-based therapies for coagulation disorders. Most recently work from her lab translated to an ongoing Phase 2b hemophilia A gene therapy trial (NCT07226206). She additionally founded and directs the CHOP clinical in vivo gene therapy group, which provides regulatory support for investigator-initiated studies, operational efforts for a large portfolio of interventional in vivo gene addition and editing trials, and clinical infrastructure to safely and efficiently implement commercial in vivo gene therapies into clinical practice. Through these collective efforts, Dr. George aims to advance safe and effective in vivo gene therapy for children with genetic disorders.
Over the three-year ELHM term, Dr. George and her fellow scholars will participate in meetings with NAM leadership and members, plan the annual Emerging Leaders Forum, contribute to National Academies convenings and publications, and attend NAM’s annual meeting. The program is designed to foster mentorship, cross-disciplinary collaboration and applied solutions to persistent challenges in health and medicine. Diana Montoya-Williams, MD, MSHP, an attending neonatologist at CHOP, was selected as a 2025 ELHM scholar.
NAM was established in 1970 as the Institute of Medicine, an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences; and beyond. It serves alongside the National Academy of Sciences and the National Academy of Engineering as an adviser to the nation and the international community. Through its domestic and global initiatives, the NAM works to address critical issues in health, medicine, and related policy and inspire positive action across sectors.
Featured in this article
Experts
Specialties & Programs
Research
Children’s Hospital of Philadelphia (CHOP) announced today that the National Academy of Medicine (NAM) named Lindsey A. George, MD, Director of Clinical In Vivo Gene Therapy, and an attending physician in the Division of Hematology at CHOP, as a member of its 2026 class of Emerging Leaders in Health and Medicine (ELHM) scholars. The ELHM program spotlights early- to mid-career professionals driving innovation across disciplines including artificial intelligence in medicine, cell and gene therapy, nanomedicine, maternal-fetal health, health economics and carceral health.
Dr. George is a physician-scientist focused on studying the molecular basis of blood clotting and developing gene-based therapies for coagulation disorders. Most recently work from her lab translated to an ongoing Phase 2b hemophilia A gene therapy trial (NCT07226206). She additionally founded and directs the CHOP clinical in vivo gene therapy group, which provides regulatory support for investigator-initiated studies, operational efforts for a large portfolio of interventional in vivo gene addition and editing trials, and clinical infrastructure to safely and efficiently implement commercial in vivo gene therapies into clinical practice. Through these collective efforts, Dr. George aims to advance safe and effective in vivo gene therapy for children with genetic disorders.
Over the three-year ELHM term, Dr. George and her fellow scholars will participate in meetings with NAM leadership and members, plan the annual Emerging Leaders Forum, contribute to National Academies convenings and publications, and attend NAM’s annual meeting. The program is designed to foster mentorship, cross-disciplinary collaboration and applied solutions to persistent challenges in health and medicine. Diana Montoya-Williams, MD, MSHP, an attending neonatologist at CHOP, was selected as a 2025 ELHM scholar.
NAM was established in 1970 as the Institute of Medicine, an independent organization of eminent professionals from diverse fields including health and medicine; the natural, social, and behavioral sciences; and beyond. It serves alongside the National Academy of Sciences and the National Academy of Engineering as an adviser to the nation and the international community. Through its domestic and global initiatives, the NAM works to address critical issues in health, medicine, and related policy and inspire positive action across sectors.
Contact us
Ashley Moore
Clinical In Vivo Gene Therapy